Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).
Clinical trial NCT05681039 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05681039
- Sponsor
- M.D. Anderson Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-02
- Primary completion
- 2026-11-01
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.